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The tumour-suppressor gene p53 is a nuclear protein which binds
to and modulates the expression of genes important for DNA
repair, cell division and cell death by apoptosis (Harris and
Hollstein, 1993; Carson and Lois, 1995). This gene regulates the
onset of DNA replication at the G1-S boundary (Vogelstein and
Kinzler, 1992), and p53 is also a component of a spindle check-
point that ensures the maintenance of diploidy (Cross et al, 1995).
Abnormalities of the p53 gene represent the most common genetic
alterations in human cancer, and at least half of all tumours have
mutations or rearrangements of both copies of the p53 gene on the
short arm of chromosome 17 (Levine et al, 1994; Soussi et al,
1994). It is now well established that most p53 missense mutations
alter the conformation of the protein leading to a prolonged half-
life. There is an accumulation in the nucleus of the tumour cell, the
levels of which can be determined using immunohistochemical
methods (Gannon et al, 1990; Levine et al, 1991).
Because wild-type p53 negatively regulates the cell cycle, a loss
of function by mutation might be expected to result in enhanced
proliferative activity and tumour progression (Chang et al, 1995).
There are reports on p53 protein accumulation in breast cancer
(Thor et al, 1992; Allred et al, 1993), lung cancer (Quinlan et al,
1992), oesophageal cancer (Shimaya et al, 1993), colon cancer
(Yamaguchi et al, 1993), laryngeal cancer (Narayana et al, 1998),
nephroblastoma (Govender et al, 1998) and gastric cancer (Martin
et al, 1992; Starzynska et al, 1992, Kakeji et al, 1993; Joypaul et
al, 1994), and survival time was shortened. These prognostic
significances of p53 expression have been investigated from the
standpoint of tumour characteristics of higher growth and
metastatic potentials (Kakeji et al, 1993; Maehara et al, 1995).
However, other studies reported controversial results regarding the
clinical value for p53 expression in various cancers (McLaren et
al, 1992; Bell et al, 1993; Brambilla et al, 1993; Motojima et al,
1994; Sarbia et al, 1994; Schneider et al, 1994; Gabbert et al,
1995; Piffk￿ et al, 1998; Suto et al, 1998). Discussions were based
on differences in patient populations, immunohistochemical
methods, and also the clinical value of p53 protein expression in
tumour advance. We investigated the possible clinical role of p53
protein expression in gastric cancer, determined using an immuno-
histochemical method. We meticulously examined data on 427
patients, using univariate and multivariate analyses.
PATIENTS AND METHODS
Patients
Between 1974 and 1991, 427 Japanese patients, with primary
gastric cancer and no evidence of malignancy in other organs,
underwent gastric resection in the Department of Surgery II,
Kyushu University Hospital, Fukuoka, Japan. Standardized proce-
dure was that gastric resection was carried out after determining
the resection line 3 cm apart from the macroscopic edge for a
localized tumour and 6 cm for an infiltrative tumour (Kawasaki,
1975; Bozzetti et al, 1982). Prophylactic lymph node dissection of
more than D2 resection was carried out (Maehara et al, 1992a).
Complete excision of invaded organs was performed, irrespective
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Medicine, Kyushu University, Fukuoka, 812-8582, Japanof the number of sites on the organs, when there was no evidence
of incurable factors such as peritoneal dissemination, liver metas-
tasis and widespread nodal involvement (Korenaga et al, 1988).
The lymph nodes in groups 1, 2 and 3 are referred to as n1, n2 and
n3, respectively, based on lymph node metastasis. Lymph node
dissection was classified as follows: D1, complete removal of
group 1 lymph node alone; D2, complete removal of group 1 and 2
lymph nodes; and D3, complete removal of group 1, 2 and 3 lymph
nodes. The pathological diagnosis and classification was
according to the General Rules for the Gastric Cancer Study in
Surgery and Pathology in Japan (Japanese Research Society for
Gastric Cancer, 1981, 1993). Curability A means no residual
tumours with a high probability of cure, under the following
conditions: no serosal invasion; n0 treated by D1, 2, 3 or n1 treated
by D2 or 3; MO, peritoneal dissemination negative (P0), liver
metastasis negative (H0); and the proximal and distal margins
> 10 mm. Curability B means no residual tumours but not evalu-
able as ￿curability A￿, and curability C shows definite residual
tumour. Tumour-advance stage was determined by the TNM clas-
sification of UICC (Sobin and Wittekind, 1997).
Three patients (0.07%) died within the first 30 post-operative
days. Of the remaining 424 patients, 173 are alive at the time of
writing this report. Recurrence of the gastric cancer and death
occurred in 173 patients, 55 died of another disease and 13 died of
undetermined causes. Death owing to causes other than gastric
cancer were considered as censored data in the statistical analysis.
p53 staining
Tissue sections were immunostained with a monoclonal antibody
against p53 (PAb1801, Oncogene Science, USA) (Banks et al,
1986; Porter et al, 1992; Sarbia et al, 1994; Oiwa et al, 1995). This
antibody recognizes a denaturation-resistant epitope between
amino acids 32 and 79 of both wild-type and mutant conforma-
tions. Xylene was used to remove paraffin from the 5-mm sections,
then the sections were progressively hydrated in decreasing
concentrations of ethanol. The slides were placed in a thermoresis-
tant beaker filled with 0.1 M phosphate-buffered saline (PBS) (pH
7.4) and autoclaved at 121°C to allow the fixed embedded tissue
antigen to react with the monoclonal antibody. The sections were
then cooled down to room temperature for about 20 min and rinsed
in PBS. These sections were then covered with normal rabbit
serum for 15 min to reduce non-specific staining, then incubated
with a 1:100 dilution of primary antibody at room temperature for
1 h. Next, the sections were washed with PBS, incubated with a
1:600 dilution of biotinylated goat anti-mouse IgG (Dako,
Denmark) at room temperature for 30 min and then covered with a
1:1000 dilution of labelled streptavidin peroxidase (Dako) at room
temperature for 30 min. The antibody was localized with 3,3¢-
diaminobenzidine tetrahydrochloride and 0.065% sodium azide
was used to block endogenous peroxidase.
We stained both the deep periphery of the tumour and adjacent
tumour-free tissue. A distinct nuclear immunoreaction for p53 was
recorded as positive, and here the nuclear staining pattern was diffuse
with little variation. When 10% of the cancer cells showed a positive
nuclear staining, a positive-staining was defined (Kakeji et al, 1993).
Post-operative chemotherapy
All of the patients with advanced stage of gastric cancer (t2—t4)
were treated with post-operative chemotherapy (Sugimachi et al,
1997). An intravenous injection of 10 mg mitomycin C (Kyowa
Hakko, Japan) was given on the day of operation, and fluorinated
pyrimidine UFT (Taiho Pharmaceutical, Japan) orally in a daily
dose of 400 mg was started 2 weeks after the operation and was
continued for 1 year.
Statistical analysis
The BMDP Statistical Package program (BMDP; Los Angeles,
CA, USA) for the IBM (Armonk, NY, USA) 3090 mainframe
computer was used for all analyses (Dixon, 1988). The BMDP
P4F and P3S programs were used for the chi-squared test and the
Mann—Whitney test to compare data from patients with p53-nega-
tive and p53-positive tumours. The BMDP P1L program was used
to analyse survival rates by the Kaplan—Meier method, and the
Mantel—Cox method to test for equality of the survival curves. The
BMDP P2L program was used for simultaneous multivariate
adjustment of all covariates by the Cox regression analysis with
the forward stepwise model (Cox, 1972). The level of significance
was P < 0.05.
RESULTS
The monoclonal antibody pAb1801 has been widely used for p53
protein expression in various cancer tissues. The positive rate of
p53 expression in gastric cancer cells was 36.8% (165 out of 427).
The staining of p53 was nuclear and p53 was never observed in the
normal gastric mucosa examined in all 427 cases, as shown in
Figure 1.
Clinicopathological factors
Table 1 shows clinicopathological data on 262 patients in whom
there was no p53 expression and for 165 patients with p53 overex-
pression. In the p53-positive patients, the entire stomach was more
likely to be involved, and the tumour was larger compared with
p53-negative cases. There were no differences in tissue differenti-
ation and growth patterns. Serosal invasion was more prominent,
lymphatic and vascular involvement was more common and the
rate of lymph node metastasis was higher in p53-positive tumours.
Surgical management was also compared between the groups
(Table 2). There was no difference with regard to the extent of
lymph node dissection. Because the entire stomach was more
commonly involved, the rate of total gastrectomy was higher in the
p53-positive patients. The rate of operative curability C (non-cura-
tive resection) was higher in p53-positive patients because of a
more advanced stage of the tumour.
Survival rates
Post-operative survival curves for patients with p53-negative and
p53-positive tumours are shown in Figure 2. The non-gastric
cancer deaths were considered as lost to follow-up, as of time of
death, and data on survivors with a follow-up time shorter than 10
years were censored from analysis. The 5-year survival rate was
62.5% for p53-negative patients and 43.3% for p53-positive
patients (P < 0.01).
Next, we determined survival rates for patients with p53-nega-
tive and p53-positive tumours for tumour size, serosal invasion,
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ative curability, which were identified as factors having a close
relation with p53 expression as shown in Tables 1 and 2. In the
subgroups of tumour size over 5 cm, serosal invasion positive,
lymphatic and vascular invasion positive and lymph node
metastasis-positive tumours, and no residual tumours by curative
resection (curability A and B), a significantly shorter survival time
was noted in p53-positive patients compared with p53-negative
patients (Table 3). Survival curves for patients with p53-negative
or p53-positive gastric cancers were determined for each node-
negative and node-positive group (Figure 3A and B).
Recurrence pattern in curatively resected patients
Data from patients with p53-positive tumours and p53-negative
tumours who underwent curative resection (curability A and B)
were analysed for recurrence patterns (Table 4). There was a recur-
rence in 39 out of 204 cases (19.1%) of p53-negative patients and
in 29 out of 106 (27.4%) of p53-positive patients. In both groups,
recurrence was noted in the peritoneum, distant organs and lymph
nodes.
Multivariate analysis of p53 protein expression
Data from Cox regression analysis of all factors are listed in Table
1, and revealed that lymph node metastasis, serosal invasion, liver
metastasis, tumour size and peritoneal dissemination proved to be
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A
B
Figure 1 Immunohistochemical detection of p53 protein in nuclei in
paraffin sections using anti-p53 monoclonal antibody PAb1801 (´ 180).
(A) Differentiated gastric carcinoma; (B) undifferentiated gastric carcinoma
Table 1 Clinicopathological characteristics of patients with p53-negative
and p53-positive gastric cancer
Variable p53 negative p53 positive P-value
(n = 262) (n = 165)
Age (years) 61.6 ± 12.5a 62.1 ± 12.6 0.6871
Sex
Men 175 (66.8) 120 (72.7) 0.1964
Women 87 (33.2) 45 (27.3)
Tumour maximal 5.89 ± 3.87a 7.33 ± 4.19 0.0002
diameter (cm)
Location of tumour
Upper 57 (21.8) 43 (26.0) 0.0285
Middle 84 (32.1) 35 (21.2)
Lower 95 (36.2) 59 (35.8)
Whole stomach 26 (9.9) 28 (17.0)
Histology
Differentiated 123 (47.3) 67 (40.6) 0.1757
Undifferentiated 137 (52.7) 98 (59.4)
Specificb 20
Serosal invasion
Negative (t1,t2) 149 (56.9) 74 (44.8) 0.0155
Positive (t3,t4) 113 (43.1) 91 (55.2)
Histological growth pattern
Expansive 45 (20.9) 25 (16.7) 0.4977
Intermediate 67 (31.2) 45 (30.0)
Infiltrative 103 (47.9) 80 (53.3)
Unknownb 47 15
Lymphatic involvement
Negative 138 (52.9) 65 (39.6) 0.0078
Positive 123 (47.1) 99 (60.4)
Unknownb 11
Vascular involvement
Negative 205 (78.5) 108 (67.1) 0.0090
Positive 56 (21.5) 53 (32.9)
Unknownb 14
Histological lymph node
metastasis
Negative 120 (46.5) 49 (29.9) 0.0007
Positive 138 (53.5) 115 (70.1)
Unknownb 41
Peritoneal dissemination
Negative 246 (93.9) 151 (91.5) 0.3492
Positive 16 (6.1) 14 (8.5)
Liver metastasis
Negative 255 (97.3) 156 (94.5) 0.1404
Positive 7 (2.7) 9 (5.5)
Stage (UICC)
Ia 80 (30.5) 28 (17.0) 0.0089
Ib 25 (9.5) 12 (7.3)
II 39 (14.9) 29 (17.6)
IIIa 51 (19.5) 30 (18.2)
IIIb 25 (9.5) 23 (13.9)
IV 42 (16.1) 43 (26.0)
NS, no significant difference; figures in parentheses are percentages; 
amean ± standard deviation; b unknown and specific cases were excluded
from statistical analysis.independent factors related to the prognosis of the patients but not
for the p53 expression. Next, we examined the independence of
p53 expression in the subgroup of lymph node metastasis-negative
and -positive patients treated with curative resection (curability A
and B). p53 expression proved to be a significant prognostic factor
in patients with node-positive gastric cancer, as shown in Table 5.
Factors of age, sex, location of the tumour, histology, histological
growth pattern and lymphatic involvement were not significant.
DISCUSSION
In this study, we made use of immunohistochemical staining to
examine the relationship between p53 expression, clinicopatho-
logical factors and survival, in tissue samples from 427 patients
resected because of gastric cancer.
Alterations in the tumour-suppressor p53 gene play a role in the
genesis of diverse types of human malignancies (Harris and
Hollstein, 1993; Soussi et al, 1994; Chang et al, 1995), and allelic
losses and point mutations in the counterpart of the locus of the
p53 gene in chromosome 17 are frequent. p53 mutation is a
common event in gastric cancer, occurring from the early stage of
progression with its specific mutation spectrum (Kim et al, 1991;
Yokozaki et al, 1992; Uchino et al, 1993). The mutated p53 gene
loses function as a tumour suppressor and can act as a dominant
oncogene (Levine et al, 1991). Loss of p53 function accelerates
the process of tumorigenesis and alters the phenotype of cancer
cells and the response of cells to agents that damage DNA (Carson
and Lois, 1995; Chang et al, 1995). Mutant-type p53 proteins have
a prolonged half-life, and are thus more likely than the wild-type
protein to be detected using immunohistochemical assays (Finlay
et al, 1988; Gannon et al, 1990; Levine et al, 1991).
The antibody PAb1801, which we used, recognizes both the
wild-type and mutant forms of p53 (Banks et al, 1986; Porter et al,
1992). No reactivity was observed in any normal gastric mucosa
adjacent to the tumour tissue and the normal protein has a very
short half-life, suggesting that the immunoreactivity of p53 in the
tumour tissue itself is likely to represent mutant forms of p53 and
relates to a more malignant biological character. Conversely,
61.4% of the gastric cancers in this study were p53 negative. The
tumours with immunohistochemically undetectable p53 could
represent a decreased availability of the epitope of p53 protein as a
result of fixation in paraffin, tumours with normal levels of wild-
type p53, tumours with both alleles of the p53 gene deleted, or
tumours expressing a mutant p53 protein not identified by the anti-
body used in this study (Gabbert et al, 1995).
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Figure 2 Survival curves for patients with p53-negative or p53-positive
gastric cancers. When the deaths were considered as gastric cancer-related,
the patients with p53-positive tumours (n = 165) had a shorter survival time
than did those with p53-negative tumours (n = 262) (P = 0.0002). Solid line,
p53-negative patients; light line, p53-positive patients
Figure 3 Survival curves for patients with p53-negative or p53-positive
gastric cancers in each node-negative and node-positive group. (A) There
was no difference between p53-negative (n = 120) and p53-positive patients
(n = 49) for the node-negative group (P = 0.9583). (B) Survival time for
p53-positive patients (n = 115) was shorter than for p53-negative patients
(n = 138) in those in the node-positive group (P = 0.0060). Solid line,
p53-negative patients; light line, p53-positive patients
Table 2 Surgical management of patients with p53-negative or p53-positive
gastric cancer
Variable p53 negative p53 positive P-value
(n = 262) (n = 165)
Operative procedure
Partial 151 (57.9) 68 (41.7) 0.0012
Total 110 (42.1) 95 (58.3)
Unknowna 12
Lymph node dissection
D0 and D1 60 (22.9) 51 (30.9) 0.0662
D2 and D3 202 (77.1) 114 (69.1)
Curability
Curability A, B 204 (78.5) 106 (64.2) 0.0030
Curability C 56 (21.5) 59 (35.8)
NS, no significant difference; figures in parentheses are percentages;
aunknown cases were excluded from statistical analysis.The p53 abnormal staining was reported to be related to the
proliferating activity of cancer cells (Kakeji et al, 1993), and
aggressive behaviour of cancer cells for serosal invasion, lymph
node metastasis of gastric cancer and a poorer prognosis ensued
(Martin et al, 1992; Starzynska et al, 1992; Joypaul et al, 1994;
Maehara et al, 1995; M￿nig et al, 1997). Because vascular and
lymphatic involvement are closely related to p53 expression, p53
expression was closely related to tumour invasion and metastasis
and, in particular, proved to be a significant prognostic factor for
node-positive cases. In cases of breast cancer, p53 expression was
closely related to prognosis for node-negative cancers (Thor et al,
1992; Allred et al, 1993). However, early stages of gastric cancer
showed no lymph node metastasis, and the post-operative prog-
nosis was improved in both p53-negative and -positive groups by
the surgical treatment (Maehara et al, 1992b, 1993).
Other investigators reported that p53 overexpression is not
related to the prognosis of human malignacies, including gastric
cancer (Motojima et al, 1994; Schneider et al, 1994; Gabbert et al,
1995). McLaren et al (1992) suggested that p53 was of consider-
able importance in the initiation of tumours in a wide variety of
tissues, but the nature of the particular oncogene involved initially
is probably of little significance once a tumour has developed. p53
protein expression could also be induced by a number of other
factors, i.e. viral infection, oncogene overexpression and transcrip-
tional activation, or mutations outside the conserved regions of
p53 (Wynford-Thomas, 1992; Bell et al, 1993). There are reports
of a combined assessment of expressions of p53 and of other
factors, for example, cyclin E and vascular endothelial growth
factor as useful factors for evaluating tumour behaviour and the
poor post-operative prognosis for subjects with various cancers
(Kang et al, 1997; Furihata et al, 1998; Sakaguchi et al, 1998;
Takahashi et al, 1998). Therefore, these approaches may further
the clinical usefulness of examining p53 expression.
The present findings show that p53 expression is closely related
to tumour invasion and metastasis and a poorer prognosis in
humans with gastric cancer. Because p53 is an integral part of anti-
cancer-related DNA damage and apoptotic pathways (Caelles et al,
1994; Carson and Lois, 1995), the clonal expansion of cells that
acquire mutations in the p53 gene reveals resistance to cancer
chemotherapy of solid tumours (Lowe et al, 1994). Post-operative
chemotherapy proved to be non-effective for p53-negative breast
cancer, therefore accumulation of p53 protein can lead to enhanced
chemoresistance (Koechli et al, 1994; Elledge et al, 1995). Chin et
al (1992) reported that the multidrug resistance gene could be acti-
vated during the tumour progression associated with mutations in
p53. Almost all of our patients with advanced gastric cancer were
prescribed post-operative chemotherapy, therefore the relation
between p53 protein expression and the effect of post-operative
chemotherapy could not be determined. An appropriate treatment
for patients with gastric cancer with p53 expression has yet to be
determined.
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Table 3 Five-year survival rate for patients with p53-negative or-positive
gastric cancer in the subgroup for each clinicopathological factor
5-year survival rate (%)
Variable p53 negative p53 positive P-valuea
Tumour size
< 5 cm 84.4 78.5 0.1228
5 cm 42.2 23.1 0.0155
Serosal invasion
Negative 94.5 97.0 0.0592
Positive 42.3 28.7 0.0027
Lymphatic invasion
Negative 79.4 72.5 0.2798
Positive 43.2 24.2 0.0039
Vascular invasion
Negative 67.4 54.2 0.0220
Positive 42.7 24.5 0.0910
Lymph node metastasis
Negative 92.7 91.4 0.9580
Positive 38.0 23.3 0.0060
Operative curability
Curability A, B 76.3 64.5 0.0284
Curability C 9.1 6.1 0.3404
NS, no significant difference; aP-values for the Mantel–Cox test.
Table 4 Recurrence after curative resection of curability A and B for
patients with p53-negative or p53-positive gastric cancer
Recurrence p53 negative p53 positive
(n = 204) (n = 106)
Without recurrence 165 (80.9) 77 (72.6)
With recurrence 39 (19.1) 29 (27.4)
Peritoneum 9 9
Liver 12 7
Lung 5 5
Bone 2 1
Brain 3 2
Local 6 4
Lymph node 4 3
Unknown 13 8
Figures in parentheses are percentages.
Table 5 Cox regression analysis for patients with node-positive gastric
cancer
Explanatory variable P-value Relative risk
(observed value) (95% confidence interval)
Tumour size 0.0001 1.1147
(per cm) (1.0693–1.1620)
Serosal invasion 0.0107 2.1984
(none, present) (1.4626–3.3042)
Venous invasion 0.0402 1.4878
(none, present) (1.0654–2.0777)
p53 overexpression 0.0486 1.3803
(none, present) (1.0034–1.8787)ACKNOWLEDGEMENTS
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